mdCurrent Conference Report: International Stroke Conference
Warfarin did not reduce the rate of the combined endpoint of death, ischemic stroke, or intracerebral hemorrhage compared with aspirin, according to a Late Breaking Clinical Trial presented at the 2012 International Stroke Conference. Both warfarin and aspirin are used in this clinical setting, but until now, the two have never been compared in a head-to-head trial in heart failure patients.
Key Point: In patients with impaired ejection fractions in normal sinus rhythm, warfarin provided no overall benefit compared with aspirin due to higher rates of intracerebral bleeding.
Patients with heart failure in sinus rhythm are at an increased risk of stroke and death due to thrombotic events; however, the preferred antithrombotic regimen for treating this population is controversial.
The prevalence of heart failure in India due to coronary heart disease, hypertension, obesity, diabetes, and rheumatic heart disease has been estimated to range from 1.3 million to 4.6 million, with...
Log in or register for free to continue reading
Register Now For Free
Already Registered? Log In
Warfarin no better than aspirin in patients with heart failure
Warfarin did not reduce the rate of the combined endpoint of death, ischemic stroke, or intracerebral hemorrhage compared with aspirin, according to a Late Breaking Clinical Trial presented at the 2012 International Stroke Conference. Both warfarin and aspirin are used in this clinical setting, but until now, the two have never been compared in a head-to-head trial in heart failure patients.
Patients with heart failure in sinus rhythm are at an increased risk of stroke and death due to thrombotic events; however, the preferred antithrombotic regimen for treating this population is controversial.
The prevalence of heart failure in India due to coronary heart disease, hypertension, obesity, diabetes, and rheumatic heart disease has been estimated to range from 1.3 million to 4.6 million, with...
Related Posts: